27.2 C
Vientiane
Wednesday, September 10, 2025
spot_img
Home Blog Page 167

DAHON-V – a Revolutionary Bike Tech Pushing a New Frontier in Green Mobility

BEIJING, Aug. 25, 2025 /PRNewswire/ — At the “JD Cycling Festival” in Beijing, China, the silver-gray, drop-bar folding bike DAHON P18 Ultra zipped past the finish line and claimed victory with lightning speed, challenging the industry’s perception that “portability and speed cannot coexist” for folding bikes. This decisive victory not only ignited a renewed interest in folding bikes among cycling enthusiasts but also brought DAHON’s proprietary bike tech DAHON-V into the spotlight for its speed.

Champion with DAHON P18 Ultra (center) and other medalists at the “JD Cycling Festival”
Champion with DAHON P18 Ultra (center) and other medalists at the “JD Cycling Festival”

DAHON-V Bike Tech: A revolutionary leap from the lab to track

The secret behind the championship of DAHON P18 Ultra lies in its DAHON-V technology suite, a set of bicycle design and testing technologies and methods that effectively address structural shortcomings found in most bikes and boost the speed of all types of bikes. It features patented technologies like DELTECH cable and Super Downtube that enable folding bikes to achieve performance levels comparable to that of road bikes for the first time.

Unleashing Freedom of Travel: From daily commuting to casual racing

Present on the DAHON P18, the pioneering “one-bike, dual-mode” design allows riders to fold and carry a bike easily onto subways or buses when folded, and switch to a road bike structure with the drop-bar after unfolding, perfectly addressing urban cyclists’ desire for both efficiency and style. Currently, DAHON’s folding bikes equipped with this technology are in high demand, reflecting the market’s strong desire for innovative products, above and beyond just a bike! 

DAHON P18 Ultra Folding Road Bike (Left), DELTECH cable (Upper right), Super Downtube (Lower right)
DAHON P18 Ultra Folding Road Bike (Left), DELTECH cable (Upper right), Super Downtube (Lower right)

Green Promise: Where speed meets sustainability

Guided by the “dual-carbon” goals, DAHON is evolving from a manufacturer into a technology enabler. Through its “Sharing 360” patent licensing program, DAHON forms strategic alliances with industry leaders such as Golden Wheel Group and Shenyang (SYB), sharing proprietary technologies to raise industry standards.

Speed Has No Limits; Innovation Knows No Bounds

From Magellan’s 37-month circumnavigation to the Wright brothers’ invention of the first flight for mankind, humanity’s pursuit of speed has always been about expanding the boundaries of freedom.

DAHON-V embodies that same spirit for the modern age: recalibrating mechanics using steel cables and algorithms, redefining the possibilities of folding and racing, and safeguarding sustainability with lightweight and smart design.

At this moment, DAHON is racing forward at “DAHON-V” speed into a greener tomorrow. As its gears turn to the rhythm of innovation, a new chapter of efficiency, freedom, and sustainability is being written—one that the world will witness together.

Speed has no limits, and DAHON is writing a new definition to unfold a new chapter of bike tech!

For more information, please contact marketing@dahon.com

www.dahon.com
usa.dahon.com

The 20th anniversary of the “Two Mountains Concept”: People’s Daily releases a promotional video-Bamboo Sees New Life

BEIJING, Aug. 25, 2025 /PRNewswire/ — August 15, 2025, marks the 20th anniversary of the “Two Mountains” concept. People’s Daily released a promotional video, “Bamboo Sees New Life”. The video tells the story of Yucun Village in Zhejiang Province. Twenty years ago, due to mountain quarrying, the mountains in Yucun became bare, and the streams were seriously polluted, whose water color was like soy sauce. However, now, it is like a beautiful traditional Chinese landscape painting. This documentary vividly depicts the practice of China’s rural revitalization, shows a rural sample of Chinese-style modernization, and serves as a vivid interpretation of General Secretary Xi Jinping’s famous statement that “lucid waters and lush mountains are invaluable assets”. 

 

People’s Daily releases a promotional video-Bamboo Sees New Life

Hear, Charge, Protect — Baseus Brings the Inspire Series and Fresh Innovations to IFA 2025

SHENZHEN, China, Aug. 25, 2025 /PRNewswire/ — Baseus, a global leader in consumer electronics, will debut its flagship Inspire series of audio products with Sound by Bose technology  — setting a new standard in accessible high-end sound at IFA 2025. Mark your calendar for September 5–10 and visit Baseus at Messe Berlin, Hall 4.2, Booth 147 for a firsthand look at the Inspire series and a showcase of cutting-edge innovations that redefine innovation, convenience, and intelligence.

Baseus Inspire Series
Baseus Inspire Series

Baseus’s Inspire audio series will take center stage at IFA 2025 with three distinct models: over-ear, open-ear, and in-ear. The open-ear design stands out with an industry-first Hybrid 2-Way Driver System in this form factor.

Hybrid 2-Way Driver System
Hybrid 2-Way Driver System

Baseus demonstrates how thoughtful acoustic engineering and pioneering hardware can elevate everyday audio experiences, setting a new benchmark for accessible premium sound.

Baseus Security X1 Pro
Baseus Security X1 Pro

Beyond audio, Baseus will spotlight its broader ecosystem. In smart security, the company will introduce the Security X1 Pro, the world’s first Smart AI Dual-Tracking Security Camera with 3K resolution and 300° of horizontal tracking range—showcasing how protection, power, and sound come together seamlessly within the Baseus experience.

Visitors can also expect the PicoGo II series of fast, travel-ready, and reliable power solutions—including compact high-output GaN chargers and Qi2.2-ready magnetic options that deliver speed and safety while fitting seamlessly with the latest flagship smartphones.

By bringing together advancements in sound, power, and security, Baseus aims to demonstrate at IFA 2025 how technology can be both innovative and accessible. The showcase underscores Baseus’s commitment to shaping smarter, more connected lifestyles for millions of users worldwide, while marking another milestone in the its journey from trusted accessory maker to global technology brand.

About Baseus

Founded in 2011, Baseus was born out of utmost care for users. The company embodies its slogan: Practical. Reliable. Base on User. This shows the pursuit of ultimate practicality to solve users’ problems with outstanding design and fashionable appearances that also reflect reliability, high quality, and cost-effectiveness. Baseus delivers a variety of products – including Portable Chargers, Desktop Chargers, Wall Chargers, Wireless Earbuds, and Docking Stations. Chosen by 300 million users and providing 6 billion services, Baseus delivers over 100 million practical and aesthetic products each year, continuously enhancing users’ sense of fulfillment. Join the Baseus family today to see a new world of technological innovation.

Media Contact:

Name: Baseus PR Team
Email: pr@baseus.com
Baseus Official Website: https://www.baseus.com/

 

Bigo Live Brings Global Creator Community Together at Turkey Mid-Year Gala


ISTANBUL, TURKEY – Media OutReach Newswire – 25 August 2025 – Bigo Live, a leading global social live-streaming platform, proudly presents its most anticipated Turkey Mid-Year Gala 2025, taking place on August 26 at the iconic Çırağan Palace Kempinski in Istanbul. Themed “Live Beyond the Screen,” the Gala celebrates the role of livestreaming in bridging cultures, empowering creators, and building meaningful connections both online and offline.

Bigo Live Brings Global Creator Community Together at Turkey Mid-Year Gala

As a key milestone in Bigo Live’s expansion across Turkey and the wider region, the event brings together over 200 top creators and business partners from across more than 15 countries and regions across Europe and Asia to honor creativity and connection. The evening will pay tribute to some of the most influential and inspiring voices on the platform through cornerstone awards, including Mid-Year GALA Family Winners, Mid-Year GALA Influencer Winners, Mid-Year GALA Agency Winners, Mid-Year GALA Creator Winners, and others. Winners will receive a specially designed trophy along with limited-edition Bigo Live merchandise and gifts in recognition of their outstanding contributions.

The Gala will also spotlight the creative diversity of Bigo Live’s global community through a vibrant mix of music, dance, and performance art. Highlights include a violin solo by Turkish artist nahidemusic, to an original vocal piece by Italian creator _kimura. Dynamic group dance performance from Commonwealth of Independent States (CIS) performers PERFECT (Bigo ID: 737040403), DIVA (Bigo ID: 7788ok), and MILA (Bigo ID: Miillamur) will bring high-energy flair to the stage, while Turkish creator BayZarif and assistant BERSSUU will offer a unique ventriloquism act blending humor and storytelling. German vocalist Nissim will add depth with a soulful performance. Traditional and contemporary Turkish dance pieces will complement the lineup, adding strong local character to this global showcase.

“The Turkey Mid-Year Gala is more than a celebration of achievement, it’s a reflection of our commitment to fostering a diverse, inclusive, and inspiring creator community,” said a Bigo Live spokesperson. “This Gala celebrates how real connections—across cultures and borders—can begin and grow through a screen.”

The Gala will also be livestreamed on Bigo Live’s official channel via the Bigo Live app, inviting a global audience to tune in and take part through real-time chat, virtual gifting, and prize opportunities. Follow Bigo Live on Instagram for updates, and join us in celebrating the transformative power of livestreaming.

Hashtag: #Bigo

The issuer is solely responsible for the content of this announcement.

AI-Powered Pet-Friendly Smart Security: Arlo Essential Indoor 2K Security Camera Offers Peace of Mind


HONG KONG SAR – Media OutReach Newswire – 25 August 2025 – Never worry about leaving your pet at home again. The Arlo Essential Indoor 2K Security Camera empowers pet owners to stay connected anytime, anywhere, with crystal-clear video, a wide field of view, night vision, and noise-canceling two-way audio. Whether you’re at work or across the globe, you can see, talk to, and comfort your furry friend with ease.

Arlo Essential Indoor 2K Security Camera
Arlo Essential Indoor 2K Security Camera

Monitor your pet 24/7 through live video, use two-way audio to guide or soothe them, and ensure their safety with real-time interaction. When you’re home, the Automated Privacy Shield, easily activated via the Arlo Secure app, protects your privacy and keeps your downtime off-camera.

Elevate your experience with an Arlo Secure subscription for cloud recording, smart notifications, and AI-powered detection. These features deliver enhanced control, sharper insights, and unmatched peace of mind for pet lovers and families.

Top Tips for Keeping Pets Safe When You’re Away:

  • Check in Regularly: Use live video to ensure your pet is safe and not getting into mischief.
  • Engage with Two-Way Audio: Comfort or redirect your pet with your voice, reinforcing commands like “stay” or “down.”
  • Stay Alert with AI Notifications: Get instant alerts for unusual activity, excessive barking, or prolonged silence to act quickly.
  • Protect Privacy: Activate the Automated Privacy Shield when you’re home to keep your pet’s (and your) downtime private.
  • Review Behavior Patterns: Access cloud recordings to spot trends or potential hazards in your pet’s routine.

With the Arlo Essential Indoor 2K Security Camera, you’re always close enough to keep your pet safe, reassured, and loved—no matter where life takes you.

Hashtag: #Arlo

The issuer is solely responsible for the content of this announcement.

About Arlo Technologies, Inc.

Arlo is an award-winning, industry leader that is transforming the ways in which people can protect everything that matters to them with advanced home, business, and personal security solutions. Arlo’s deep expertise in AI- and CV-powered analytics, cloud services, user experience and product design, and innovative wireless and RF connectivity enables the delivery of a seamless, smart security experience for Arlo users that is easy to set up and interact with every day. Arlo’s cloud-based platform provides users with visibility, insight, and a powerful means to help protect and connect in real-time with the people and things that matter most, from any location with a Wi-Fi or a cellular connection. Arlo has recently launched several categories of award-winning connected devices, software, and services. These include wire-free, smart Wi-Fi and LTE-enabled security cameras, video doorbells, floodlights, security system, and Arlo’s subscription services: Arlo Secure and Arlo Safe.

With a mission to bring users peace of mind, Arlo is as passionate about protecting user privacy as it is about safeguarding homes and families. Arlo is committed to implementing industry standards for data protection designed to keep users’ personal information private and in their control. Arlo provides enhanced controls for user data, supports privacy legislation, keeps user data safely secure, and puts security at the forefront of company culture.

NX China Exhibits at 3rd China International Supply Chain Expo (CISCE) in Beijing

TOKYO, Aug. 25, 2025 /PRNewswire/ — Nippon Express (China) Co., Ltd. (hereafter “NX China”), a group company of NIPPON EXPRESS HOLDINGS, INC., participated in the 3rd China International Supply Chain Expo (CISCE) held at the China International Exhibition Center in Beijing, China from Wednesday, July 16 to Sunday, July 20.

Logo: https://drive.google.com/file/d/1dqm0cxpYamnvMUra1AGXMuGlX932Z353/view?usp=drive_link 

Group photo of NX China staff at the CISCE booth: https://drive.google.com/file/d/1uDoYmQl5_2-iNPax8ZuLjxw1YwpL4vJt/view?usp=drive_link 

Organized by the China Council for the Promotion of International Trade (CCPIT), the CISCE is China’s largest exhibition dedicated to the theme of supply chains. Now in its third year, the expo welcomed approximately 650 companies from around 75 countries and regions, with the proportion of overseas exhibitors reaching a record high of 35%. The event concluded successfully, attracting a total of 210,000 visitors, including both industry professionals and the general public.*

*Including online attendees

NX China presented the NX Group’s wide range of logistics solutions, leveraging its strengths as a global logistics company. Its booth highlighted cross-border logistics services as well as international transport solutions utilizing the ChinaEurope railway, which attracted considerable interest from numerous visitors.

The NX Group remains committed to meeting the logistics challenges of its customers and supporting their business expansion with its global network and accumulated expertise in advanced logistics.

About the NX Group: https://drive.google.com/file/d/1mbvBL6C8THZNrR5LREgGeafNkEdaAmV-/view?usp=drive_link 

NX Group official website: https://www.nipponexpress.com/ 

NX Group’s official LinkedIn account: https://www.linkedin.com/company/nippon-express-group/ 

Slow Travel Takes Hold in Bali with New Movenpick Bali Long-Stay Package

BALI, Indonesia, Aug. 25, 2025 /PRNewswire/ — It’s late afternoon in Jimbaran and the pace feels unhurried. The sun drifts lower over the bay, fishermen haul in their nets, and visitors wander between market stalls or settle in for coffee at open-air cafés. This is a quieter side of Bali, one that rewards those who take their time.

A family holiday comes alive at Mövenpick Resort & Spa Jimbaran Bali, where comfort, relaxation, and joy meet in perfect harmony.
A family holiday comes alive at Mövenpick Resort & Spa Jimbaran Bali, where comfort, relaxation, and joy meet in perfect harmony.

Travellers are beginning to embrace this slower rhythm, choosing longer stays and gentler itineraries instead of packing their days with back-to-back activities. It’s less about ticking off the big-name sights and more about enjoying simple pleasures – a morning swim, a leisurely lunch, an afternoon nap, or a massage that lingers well into the evening.

Tapping into that shift, Mövenpick Resort & Spa Jimbaran Bali has launched its Holiday Saver package, designed to encourage guests to linger longer. The offer is available for stays of five nights or more between 1 August 2025 and 31 March 2026, with bookings open from 1 August to 30 September 2025.

The inclusions are thoughtful, catering to those unhurried days. Guests receive breakfast each morning, one daily meal at the resort’s restaurants, a daily cocktail, the brand’s signature Chocolate Hour in the afternoon, and a 60-minute massage for two once per stay. Rates begin at IDR 2,600,000++ per night, with Accor Plus members enjoying an additional 10% off.

“People aren’t just sightseeing anymore,” says Dedy Sulistiyanto, the resort’s Marketing & Communications Manager. “They want to immerse themselves in the local way of life – whether that means sampling Balinese flavours, strolling through Jimbaran at sunset, or simply pausing by the pool with nothing on the agenda.”

The resort itself lends naturally to this slower style of travel. Nestled within the lively Samasta Lifestyle Village, it offers easy access to shops, cafés, and entertainment, while Jimbaran Beach and cultural landmarks such as Garuda Wisnu Kencana are just a short drive away. Guests can weave between laid-back resort living and authentic Balinese experiences at their own pace.

By blending comfort with a strong sense of place, the Holiday Saver makes it easy for travellers to trade a rushed getaway for something deeper and more restorative. It’s an invitation to slow down, stay a little longer, and discover a Bali that reveals itself only when you take the time.

Bookings and details Resort.Bali.Reservations@movenpick.com 

or visit https://movenpick.accor.com/en/asia/indonesia/bali/jimbaran-bali/hotel-offers/Holiday_Saver.html

Follow us on social media:

Facebook: https://www.facebook.com/movenpickbali/

Twitter: https://twitter.com/movenpickbali/

Instagram: https://www.instagram.com/movenpickbali/

Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4Rα) for Atopic Dermatitis Achieve Primary Endpoints

HONG KONG, Aug. 25, 2025 /PRNewswire/ — Akeso Inc. (9926.HK) (“Akeso” or “the Company”) today announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis (AS). The study successfully met all primary efficacy endpoints, including ASAS20 and subgroup analyses, as well as the key secondary endpoint ASAS40. Furthermore, several pre-specified secondary endpoints demonstrated both statistically significant and clinically meaningful improvements, further supporting the potential of gumokimab as an effective treatment option for AS.

Gumokimab rapidly and effectively alleviated AS symptoms, significantly improved disease activity and enhanced physical function and quality of life in patients. This promising new treatment option may offer a much-needed solution for the approximately 4 million AS patients in China. Notably, gumokimab has already shown positive results in a Phase 3 pivotal trial for moderate-to-severe psoriasis, with the New Drug Application (NDA) for this indication accepted by the NMPA CDE in January 2025. The NDA submission for moderate-to-severe psoriasis marks gumokimab as Akeso’s third non-oncology drug to enter the market approval process.

In addition, Akeso reported that its novel fully human anti-IL-4Rα monoclonal antibody, manfidokimab (AK120), has also achieved positive outcomes in its Phase 3 clinical trial for moderate-to-severe atopic dermatitis (AD). The study met all primary endpoints, key secondary endpoints, several pre-specified secondary endpoints, and demonstrated statistically significant and clinically relevant improvements in patients.

Manfidokimab notably improved skin lesions and provided excellent early relief of pruritus, offering a potentially transformative treatment for patients with moderate-to-severe AD. As a result of the strong efficacy and safety profile demonstrated in this trial, Akeso plans to file an NDA for manfidokimab in this indication, aiming to provide a more effective and domestically developed IL-4Rα-targeting biologics for AD patients in China. Manfidokimab will be Akeso’s fourth non-oncology drug to enter the NDA phase and represents a significant milestone in the company’s expanding autoimmune pipeline.

With the successful market launches of ebronucimab (PCSK9) and ebdarokimab (IL-12/IL-23), along with the recent positive Phase 3 studies from gumokimab (IL-17) and from manfidokimab (IL-4Rα), Akeso’s non-oncology franchise is rapidly expanding and will provide a future driver for commercial growth. Akeso’s expanding non-oncology product portfolio is further strengthened by a robust pipeline of innovative biologics that includes our first in class IL-4R/ST2 bispecific antibody and candidates for neurodegenerative diseases. The combination of commercial launches, Phase III successes and innovation-focused pipeline will increase Akeso’s competitive position globally in non-oncology indications.

Forward-Looking Statement of Akeso, Inc.
This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.